Literature DB >> 17894850

Outcome of screening for hepatitis C virus infection based on risk factors.

Carol Mallette1, Maura A Flynn, Kittichai Promrat.   

Abstract

OBJECTIVES: Screening for hepatitis C virus (HCV) infection in individuals at increased risk is currently recommended by most, but not all, health authorities. This study identifies outcomes of individuals diagnosed through a screening program targeting high-risk patients.
METHODS: Veterans presenting for care in VA facilities are assessed for HCV risk factors by a questionnaire. Those with a risk factor are offered anti-HCV testing. Between October 1998 and May 2004, 25,701 patients were assessed and 8,471 patients had a risk factor for HCV. Patients diagnosed through the screening program were assessed per study protocol.
RESULTS: The prevalence of a positive HCV antibody in veterans who identified a risk factor was 7.3% (95% CI 6.6-8.0%). Among those diagnosed through the screening program (N = 260), 47% had chronic hepatitis C. Among patients with chronic HCV, 18% had evidence of advanced liver disease (stage III/IV on biopsy or clinical cirrhosis) while 34% had persistently normal alanine aminotransferase (ALT). Two-thirds of individuals who underwent liver biopsy had minimal or no fibrosis. About half (47%) of the screen-detected patients with chronic HCV were treatment candidates. Forty-four percent were not immediate candidates secondary to medical or psychiatric comorbidities or active substance abuse. Twenty-two patients (8%) had died after a median follow-up of 911 days. Two were liver-related deaths.
CONCLUSION: Screening for hepatitis C in persons at high risk can lead to early identification of individuals at risk for progressive liver disease who may benefit from antiviral therapy and counseling to reduce HCV-related liver injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894850     DOI: 10.1111/j.1572-0241.2007.01522.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  A Canadian screening program for hepatitis C: is now the time?

Authors:  Hemant A Shah; Jenny Heathcote; Jordan J Feld
Journal:  CMAJ       Date:  2013-09-30       Impact factor: 8.262

Review 2.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

3.  Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans.

Authors:  Nghia H Nguyen; Philip Vutien; Huy N Trinh; Ruel T Garcia; Long H Nguyen; Huy A Nguyen; Khanh K Nguyen; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2010-04-09       Impact factor: 6.047

Review 4.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

5.  Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population.

Authors:  Engy Mohamed El-Ghitany; Azza Galal Farghaly; Shehata Farag; Ekram Wassim Abd El-Wahab
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

6.  Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States.

Authors:  Shan Liu; Lauren E Cipriano; Mark Holodniy; Jeremy D Goldhaber-Fiebert
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

7.  Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.

Authors:  Rui Fu; Alexander Gutfraind; Margaret L Brandeau
Journal:  Math Biosci       Date:  2016-01-14       Impact factor: 3.935

8.  Assessment of hepatitis C risk factors in center of Iran: A case-control study.

Authors:  Faramarz Shahriari-Fard; Sayed Moayed Alavian; Ziba Farajzadegan; Ali Rabiei; Behrooz Ataei; Mehdi Ataie
Journal:  J Res Med Sci       Date:  2018-10-26       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.